The debate over how much fluid to give patients with sepsis is far from settled. Three major randomized controlled trials (RCTs) conducted since 2020 tried to answer the question, pitting “restrictive” fluid resuscitation against “liberal” strategies. Despite differences in how they defined “restrictive” and “liberal,” and in their specific patient criteria, all three studies landed in the same place: there was no difference in the primary outcome, no matter how much crystalloid was given during the initial resuscitation.
What’s especially striking is that patients had already received between 1.5 to 3.0 liters of crystalloid before even being officially enrolled in these trials. In other words, a hefty chunk of their fluid resuscitation was completed before researchers started measuring outcomes. And for anyone who remembers the Rivers trial—where both arms received a whopping 13.5 liters of fluid by 72 hours—it’s clear that crystalloid has long been the “apex predator” in sepsis care.
EGDT: More Cost, Longer ICU Stays, No Difference in Survival
Another persistent question in sepsis care has been the value of early goal-directed therapy (EGDT). According to the data, EGDT was more costly and led to longer ICU stays, but didn’t budge the primary outcomes compared to more basic approaches. In fact, the aggressive fluid targets baked into EGDT protocols now appear to be, well, a little too aggressive for most patients. When outcomes were broken down by subgroup, there still wasn’t any evidence that tweaking fluid volumes within the first 24 hours made a real difference.
Dr. Aaron B. Holley, professor of medicine at the Uniformed Services University and a critical care physician at MedStar Washington Hospital Center, points out that a 1–2 liter difference in crystalloid at 24 hours just doesn’t change the game for most people with sepsis. The field has shifted: “We kept the ‘E’ [for early], but ditched the specific goals and most of the therapies,” Holley explained, summing up the move away from rigid protocols.
So, while the sepsis fluid debate rages on, the latest evidence suggests clinicians can worry less about hitting a precise fluid number and more about the bigger picture—tailoring care to each patient, without fear of missing a “magic” target.
